IHH Healthcare Bhd reported a net profit attributable to owners of the company of RM2.1 billion for the financial year ended 31 Dec 2025, down 21 per cent year-on-year, as unrealised foreign-exchange losses from a stronger ringgit offset solid operating gains in its key markets.
Group revenue rose 6 per cent year-on-year to RM25.7 billion. The company did not release earnings-per-share data. The board declared a second and final dividend of 10.5 sen per share, up from 10 sen a year earlier; payment details will be announced later, subject to shareholder approval.
On a constant-currency basis, core revenue increased 18 per cent to RM26.2 billion and core profit after tax and minority interests (excluding exceptional items) grew 3 per cent to RM2.3 billion. Segmentally, Malaysia benefited from higher medical-tourism volumes and expanding day-case procedures, while India continued to gain from synergies following the maintenance services agreement between Fortis Healthcare and Gleneagles India. Singapore operations remained resilient, and Gleneagles Hong Kong reached break-even in December on stronger inpatient traffic.
The decline in reported earnings was mainly attributable to “paper losses” on currency translation, management said. Net debt to EBITDA stood at 2.4 times as at 31 Dec 2025, and return on equity (excluding exceptional items and MFRS129 effects) was about 9 per cent.
Looking ahead, the group expects growth to be underpinned by: • Further expansion of day-care volumes in Malaysia to mitigate payor pressure and medical-cost inflation; • Stabilisation of contributions from the new Mount Elizabeth Orchard facility in Singapore by the second half of 2026; • Additional clinical and operational synergies in India following the completion of the Fortis acquisition; and • Continued focus on sustaining market leadership and operational resilience in Türkiye.
Group chief executive officer Dr Prem Kumar Nair said the FY2025 performance reflected early gains from the company’s multi-year transformation programme. He noted that investments in staff capability and technology-driven productivity, coupled with an emphasis on clinical excellence, are intended to lift return on equity to double-digit levels by 2028.